[Intravenous infusion of XXXX (a beta-2-mimetic agent) in the therapy of severe @entity565 attacks in childhood].

@entity1 @entity565 @entity3045 @entity26 @entity591 @entity400 @entity1576 @entity73101 @entity617
20 @entity1 (age range 0.8-14.7 years) with acute severe @entity565 were alternately randomized to receive one of two different treatment regimes. 10 @entity1 (control-group) received @entity3045 inhalation (75 micrograms/kg in 2 ml Saline every two hours). 10 @entity1 ( @entity73101 -group) received @entity73101 infusion (0.2-2.0 micrograms/kg/min in Saline) and inhaled Saline only. Other therapy regimen were identical in both groups: Theophylline infusion, i.v. @entity617 , adequate fluids intake and @entity26 insufflation. Age, severity and maintenance therapy of @entity565 , and severity of the acute episode, were not significantly different in both groups. Treatment efficacy, assessed with a simple clinical score, the heart and respiratory rates, the peak expiratory flow (PEF) and the blood gases, was comparable in both groups. Side effects, i.e. @entity591 , blood pressure changes and @entity400 , were also similar and clinically not relevant in both groups. In two @entity1 , who previously needed repeated mechanical ventilation, severe @entity1576 could be successfully controlled only when the @entity73101 dose was raised 10 folds (2.0 micrograms/kg/min). @entity73101 infusion can be recommended in @entity1 with acute severe @entity565 , who do not respond satisfactorily to current therapy regimen, particularly in @entity1 who previously experienced numerous intubations.
